nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K1—epithelium—cervical cancer	0.0236	0.0866	CbGeAlD
Trametinib—MAP2K1—renal system—cervical cancer	0.0219	0.0803	CbGeAlD
Trametinib—MAP2K2—uterine cervix—cervical cancer	0.0206	0.0756	CbGeAlD
Trametinib—MAP2K2—decidua—cervical cancer	0.0196	0.072	CbGeAlD
Trametinib—MAP2K2—renal system—cervical cancer	0.0192	0.0707	CbGeAlD
Trametinib—MAP2K2—endometrium—cervical cancer	0.0186	0.0684	CbGeAlD
Trametinib—MAP2K2—mammalian vulva—cervical cancer	0.018	0.0661	CbGeAlD
Trametinib—MAP2K1—female reproductive system—cervical cancer	0.0175	0.0643	CbGeAlD
Trametinib—MAP2K2—uterus—cervical cancer	0.0171	0.063	CbGeAlD
Trametinib—MAP2K1—female gonad—cervical cancer	0.0159	0.0585	CbGeAlD
Trametinib—MAP2K2—female reproductive system—cervical cancer	0.0154	0.0566	CbGeAlD
Trametinib—CYP3A4—Topotecan—cervical cancer	0.0148	1	CbGbCtD
Trametinib—MAP2K2—female gonad—cervical cancer	0.014	0.0515	CbGeAlD
Trametinib—Mucosal inflammation—Topotecan—cervical cancer	0.0129	0.081	CcSEcCtD
Trametinib—MAP2K1—lymph node—cervical cancer	0.0102	0.0376	CbGeAlD
Trametinib—Rash erythematous—Topotecan—cervical cancer	0.00933	0.0586	CcSEcCtD
Trametinib—MAP2K2—lymph node—cervical cancer	0.00902	0.0331	CbGeAlD
Trametinib—Hyperbilirubinaemia—Topotecan—cervical cancer	0.00786	0.0493	CcSEcCtD
Trametinib—CYP2C8—renal system—cervical cancer	0.00667	0.0245	CbGeAlD
Trametinib—Rash maculo-papular—Topotecan—cervical cancer	0.00649	0.0408	CcSEcCtD
Trametinib—Neoplasm—Topotecan—cervical cancer	0.00646	0.0406	CcSEcCtD
Trametinib—CYP2C8—endometrium—cervical cancer	0.00644	0.0237	CbGeAlD
Trametinib—CYP2C8—female reproductive system—cervical cancer	0.00534	0.0196	CbGeAlD
Trametinib—CYP2C8—vagina—cervical cancer	0.00483	0.0177	CbGeAlD
Trametinib—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.00467	0.0293	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00457	0.0287	CcSEcCtD
Trametinib—CYP3A4—renal system—cervical cancer	0.00451	0.0166	CbGeAlD
Trametinib—Neutropenia—Topotecan—cervical cancer	0.00419	0.0263	CcSEcCtD
Trametinib—Infestation NOS—Topotecan—cervical cancer	0.004	0.0251	CcSEcCtD
Trametinib—Infestation—Topotecan—cervical cancer	0.004	0.0251	CcSEcCtD
Trametinib—Stomatitis—Topotecan—cervical cancer	0.0039	0.0245	CcSEcCtD
Trametinib—Epistaxis—Topotecan—cervical cancer	0.00377	0.0237	CcSEcCtD
Trametinib—CYP3A4—female reproductive system—cervical cancer	0.00362	0.0133	CbGeAlD
Trametinib—Haemoglobin—Topotecan—cervical cancer	0.00361	0.0226	CcSEcCtD
Trametinib—Haemorrhage—Topotecan—cervical cancer	0.00359	0.0225	CcSEcCtD
Trametinib—Angiopathy—Topotecan—cervical cancer	0.00325	0.0204	CcSEcCtD
Trametinib—Mediastinal disorder—Topotecan—cervical cancer	0.00323	0.0203	CcSEcCtD
Trametinib—Chills—Topotecan—cervical cancer	0.00322	0.0202	CcSEcCtD
Trametinib—Malnutrition—Topotecan—cervical cancer	0.00312	0.0196	CcSEcCtD
Trametinib—Back pain—Topotecan—cervical cancer	0.00302	0.019	CcSEcCtD
Trametinib—Muscle spasms—Topotecan—cervical cancer	0.003	0.0189	CcSEcCtD
Trametinib—Anaemia—Topotecan—cervical cancer	0.00289	0.0181	CcSEcCtD
Trametinib—Leukopenia—Topotecan—cervical cancer	0.0028	0.0176	CcSEcCtD
Trametinib—Cough—Topotecan—cervical cancer	0.00273	0.0171	CcSEcCtD
Trametinib—Arthralgia—Topotecan—cervical cancer	0.00266	0.0167	CcSEcCtD
Trametinib—Myalgia—Topotecan—cervical cancer	0.00266	0.0167	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00264	0.0166	CcSEcCtD
Trametinib—Infection—Topotecan—cervical cancer	0.00253	0.0159	CcSEcCtD
Trametinib—Nervous system disorder—Topotecan—cervical cancer	0.0025	0.0157	CcSEcCtD
Trametinib—Thrombocytopenia—Topotecan—cervical cancer	0.0025	0.0157	CcSEcCtD
Trametinib—Skin disorder—Topotecan—cervical cancer	0.00248	0.0155	CcSEcCtD
Trametinib—Hyperhidrosis—Topotecan—cervical cancer	0.00246	0.0155	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00232	0.0146	CcSEcCtD
Trametinib—Decreased appetite—Topotecan—cervical cancer	0.00222	0.0139	CcSEcCtD
Trametinib—Gastrointestinal disorder—Topotecan—cervical cancer	0.0022	0.0138	CcSEcCtD
Trametinib—Fatigue—Topotecan—cervical cancer	0.0022	0.0138	CcSEcCtD
Trametinib—Constipation—Topotecan—cervical cancer	0.00218	0.0137	CcSEcCtD
Trametinib—Gastrointestinal pain—Topotecan—cervical cancer	0.00208	0.0131	CcSEcCtD
Trametinib—Body temperature increased—Topotecan—cervical cancer	0.00201	0.0127	CcSEcCtD
Trametinib—Abdominal pain—Topotecan—cervical cancer	0.00201	0.0127	CcSEcCtD
Trametinib—Asthenia—Topotecan—cervical cancer	0.00183	0.0115	CcSEcCtD
Trametinib—Pruritus—Topotecan—cervical cancer	0.0018	0.0113	CcSEcCtD
Trametinib—Diarrhoea—Topotecan—cervical cancer	0.00174	0.011	CcSEcCtD
Trametinib—Dizziness—Topotecan—cervical cancer	0.00169	0.0106	CcSEcCtD
Trametinib—Vomiting—Topotecan—cervical cancer	0.00162	0.0102	CcSEcCtD
Trametinib—Rash—Topotecan—cervical cancer	0.00161	0.0101	CcSEcCtD
Trametinib—Dermatitis—Topotecan—cervical cancer	0.00161	0.0101	CcSEcCtD
Trametinib—Headache—Topotecan—cervical cancer	0.0016	0.01	CcSEcCtD
Trametinib—Nausea—Topotecan—cervical cancer	0.00151	0.00951	CcSEcCtD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—FGFR3—cervical cancer	0.000989	0.00179	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by VEGF—CTNNB1—cervical cancer	0.000983	0.00178	CbGpPWpGaD
Trametinib—MAP2K1—VEGFA-VEGFR2 Pathway—CTNNB1—cervical cancer	0.000974	0.00176	CbGpPWpGaD
Trametinib—MAP2K1—Oncostatin M Signaling Pathway—TP53—cervical cancer	0.000966	0.00174	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—EGFR—cervical cancer	0.000955	0.00172	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HLA-DQB1—cervical cancer	0.000948	0.00171	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—TAAR6—cervical cancer	0.000945	0.00171	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—MTOR—cervical cancer	0.000942	0.0017	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—CASP8—cervical cancer	0.000931	0.00168	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—MTOR—cervical cancer	0.000926	0.00167	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—FGFR3—cervical cancer	0.000925	0.00167	CbGpPWpGaD
Trametinib—MAP2K2—ErbB1 downstream signaling—STAT3—cervical cancer	0.000922	0.00166	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by VEGF—CTNNB1—cervical cancer	0.00092	0.00166	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—MTOR—cervical cancer	0.000901	0.00163	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by Interleukins—STAT3—cervical cancer	0.000901	0.00163	CbGpPWpGaD
Trametinib—MAP2K2—L1CAM interactions—EGFR—cervical cancer	0.0009	0.00162	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—MTOR—cervical cancer	0.000887	0.0016	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—MTOR—cervical cancer	0.000881	0.00159	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—MTOR—cervical cancer	0.000867	0.00156	CbGpPWpGaD
Trametinib—MAP2K1—ErbB1 downstream signaling—STAT3—cervical cancer	0.000862	0.00156	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways in Glioblastoma—TP53—cervical cancer	0.000857	0.00155	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—CASP3—cervical cancer	0.000852	0.00154	CbGpPWpGaD
Trametinib—MAP2K2—Insulin Signaling—MTOR—cervical cancer	0.000851	0.00154	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—MTOR—cervical cancer	0.000847	0.00153	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—MTOR—cervical cancer	0.000843	0.00152	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by Interleukins—STAT3—cervical cancer	0.000843	0.00152	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—MTOR—cervical cancer	0.000843	0.00152	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—MTOR—cervical cancer	0.000843	0.00152	CbGpPWpGaD
Trametinib—MAP2K1—L1CAM interactions—EGFR—cervical cancer	0.000842	0.00152	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.00084	0.00152	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—MTOR—cervical cancer	0.000839	0.00151	CbGpPWpGaD
Trametinib—MAP2K2—ErbB1 downstream signaling—EGFR—cervical cancer	0.000838	0.00151	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—MTOR—cervical cancer	0.000835	0.00151	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—MTOR—cervical cancer	0.00083	0.0015	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—CTNNB1—cervical cancer	0.000821	0.00148	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—TP53—cervical cancer	0.000802	0.00145	CbGpPWpGaD
Trametinib—MAP2K2—PDGFR-beta signaling pathway—STAT3—cervical cancer	0.000802	0.00145	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—CASP3—cervical cancer	0.000797	0.00144	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—MTOR—cervical cancer	0.000797	0.00144	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—MTOR—cervical cancer	0.000793	0.00143	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—MTOR—cervical cancer	0.000789	0.00142	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—MTOR—cervical cancer	0.000789	0.00142	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—WNT2—cervical cancer	0.000788	0.00142	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—MTOR—cervical cancer	0.000785	0.00142	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—MTOR—cervical cancer	0.000785	0.00142	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—MTOR—cervical cancer	0.000785	0.00142	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—MTOR—cervical cancer	0.000785	0.00142	CbGpPWpGaD
Trametinib—MAP2K1—ErbB1 downstream signaling—EGFR—cervical cancer	0.000784	0.00142	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—MTOR—cervical cancer	0.000781	0.00141	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—MTOR—cervical cancer	0.000778	0.00141	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—MTOR—cervical cancer	0.000771	0.00139	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—CTNNB1—cervical cancer	0.000768	0.00139	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—MTOR—cervical cancer	0.000768	0.00139	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—FGFR3—cervical cancer	0.000761	0.00137	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—CASP3—cervical cancer	0.000753	0.00136	CbGpPWpGaD
Trametinib—MAP2K1—PDGFR-beta signaling pathway—STAT3—cervical cancer	0.00075	0.00135	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—WNT2—cervical cancer	0.000738	0.00133	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—MTOR—cervical cancer	0.000735	0.00133	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—MTOR—cervical cancer	0.000735	0.00133	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—MTOR—cervical cancer	0.000735	0.00133	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—MTOR—cervical cancer	0.000728	0.00131	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—STAT3—cervical cancer	0.000728	0.00131	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—MTOR—cervical cancer	0.000722	0.0013	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—MTOR—cervical cancer	0.000719	0.0013	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—STAT3—cervical cancer	0.000716	0.00129	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—FGFR3—cervical cancer	0.000712	0.00128	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—UBE3A—cervical cancer	0.00071	0.00128	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—CASP3—cervical cancer	0.000705	0.00127	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—MTOR—cervical cancer	0.000696	0.00126	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKAP13—cervical cancer	0.000692	0.00125	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—STAT3—cervical cancer	0.000681	0.00123	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—STAT3—cervical cancer	0.00067	0.00121	CbGpPWpGaD
Trametinib—MAP2K2—Disease—WNT2—cervical cancer	0.000665	0.0012	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—UBE3A—cervical cancer	0.000664	0.0012	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—EGFR—cervical cancer	0.000662	0.00119	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—TP53—cervical cancer	0.000658	0.00119	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—CTNNB1—cervical cancer	0.000658	0.00119	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—STAT3—cervical cancer	0.000655	0.00118	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	0.000652	0.00118	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—MTOR—cervical cancer	0.000651	0.00118	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKAP13—cervical cancer	0.000648	0.00117	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000636	0.00115	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—EGFR—cervical cancer	0.000633	0.00114	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of Actin Cytoskeleton—EGFR—cervical cancer	0.000633	0.00114	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—EGFR—cervical cancer	0.000623	0.00113	CbGpPWpGaD
Trametinib—MAP2K1—Disease—WNT2—cervical cancer	0.000622	0.00112	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—EGFR—cervical cancer	0.000619	0.00112	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—CTNNB1—cervical cancer	0.000616	0.00111	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000613	0.00111	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—STAT3—cervical cancer	0.000613	0.00111	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—HES1—cervical cancer	0.000611	0.0011	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	0.00061	0.0011	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—STAT3—cervical cancer	0.000607	0.0011	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—WNT5A—cervical cancer	0.000598	0.00108	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TAAR6—cervical cancer	0.000597	0.00108	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—EGFR—cervical cancer	0.000595	0.00107	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—STAT3—cervical cancer	0.000594	0.00107	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of Actin Cytoskeleton—EGFR—cervical cancer	0.000592	0.00107	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—EGFR—cervical cancer	0.000592	0.00107	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—EGFR—cervical cancer	0.000592	0.00107	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	0.000592	0.00107	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—EGFR—cervical cancer	0.000589	0.00106	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—EGFR—cervical cancer	0.000586	0.00106	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—TP53—cervical cancer	0.000586	0.00106	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—EGFR—cervical cancer	0.000583	0.00105	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—EGFR—cervical cancer	0.000575	0.00104	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—HES1—cervical cancer	0.000571	0.00103	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—STAT3—cervical cancer	0.000568	0.00103	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—WNT5A—cervical cancer	0.000559	0.00101	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TAAR6—cervical cancer	0.000558	0.00101	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—EGFR—cervical cancer	0.000557	0.00101	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—STAT3—cervical cancer	0.000555	0.001	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—EGFR—cervical cancer	0.000554	0.001	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	0.000554	0.001	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—EGFR—cervical cancer	0.000552	0.000996	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	0.000552	0.000996	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—EGFR—cervical cancer	0.000552	0.000996	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—EGFR—cervical cancer	0.000551	0.000995	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—EGFR—cervical cancer	0.000549	0.000991	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—TP53—cervical cancer	0.000548	0.000989	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—EGFR—cervical cancer	0.000547	0.000987	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—EGFR—cervical cancer	0.000542	0.000978	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—EGFR—cervical cancer	0.000539	0.000974	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—EGFR—cervical cancer	0.000538	0.000972	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	0.000538	0.000971	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—MTOR—cervical cancer	0.000535	0.000966	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—EGFR—cervical cancer	0.000521	0.000941	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—EGFR—cervical cancer	0.000516	0.000932	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—EGFR—cervical cancer	0.000516	0.000932	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	0.000516	0.000932	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—EGFR—cervical cancer	0.000512	0.000924	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—EGFR—cervical cancer	0.000507	0.000915	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—EGFR—cervical cancer	0.000505	0.000911	CbGpPWpGaD
Trametinib—MAP2K2—Disease—WNT5A—cervical cancer	0.000504	0.00091	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	0.000503	0.000908	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—MTOR—cervical cancer	0.000501	0.000904	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—CASP3—cervical cancer	0.000492	0.000889	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	0.000489	0.000882	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—EGFR—cervical cancer	0.000488	0.000881	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000486	0.000877	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TP53—cervical cancer	0.000483	0.000872	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.000472	0.000853	CbGpPWpGaD
Trametinib—MAP2K1—Disease—WNT5A—cervical cancer	0.000472	0.000852	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—WNT2—cervical cancer	0.000466	0.000841	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—NOTCH1—cervical cancer	0.000461	0.000833	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—CASP3—cervical cancer	0.00046	0.000831	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	0.000457	0.000825	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TP53—cervical cancer	0.000452	0.000816	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	0.000442	0.000798	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—WNT2—cervical cancer	0.000436	0.000787	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—FGFR3—cervical cancer	0.000434	0.000783	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NOTCH1—cervical cancer	0.000431	0.000779	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-DPB1—cervical cancer	0.000424	0.000765	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—STAT3—cervical cancer	0.000421	0.000759	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—STAT3—cervical cancer	0.000413	0.000747	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKAP13—cervical cancer	0.000409	0.000738	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000408	0.000736	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—FGFR3—cervical cancer	0.000406	0.000733	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-DPB1—cervical cancer	0.000396	0.000716	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—STAT3—cervical cancer	0.000393	0.00071	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—STAT3—cervical cancer	0.000387	0.000698	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKAP13—cervical cancer	0.000383	0.000691	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—EGFR—cervical cancer	0.000376	0.000679	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CASP8—cervical cancer	0.000371	0.00067	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—WNT5A—cervical cancer	0.000353	0.000637	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—EGFR—cervical cancer	0.000352	0.000635	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CASP8—cervical cancer	0.000347	0.000627	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—EGFR—cervical cancer	0.00034	0.000614	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HLA-DQB1—cervical cancer	0.000331	0.000597	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—WNT5A—cervical cancer	0.00033	0.000596	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—EGFR—cervical cancer	0.000318	0.000575	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HLA-DQB1—cervical cancer	0.000309	0.000559	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD8A—cervical cancer	0.000309	0.000558	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—CTNNB1—cervical cancer	0.000306	0.000553	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MTOR—cervical cancer	0.000305	0.000551	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CD4—cervical cancer	0.000305	0.00055	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HES1—cervical cancer	0.00029	0.000524	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD8A—cervical cancer	0.000289	0.000522	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—CTNNB1—cervical cancer	0.000287	0.000518	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MTOR—cervical cancer	0.000286	0.000516	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CD4—cervical cancer	0.000285	0.000515	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HES1—cervical cancer	0.000271	0.00049	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CTNNB1—cervical cancer	0.000271	0.000489	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—STAT3—cervical cancer	0.000267	0.000482	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MTHFR—cervical cancer	0.000255	0.00046	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TERT—cervical cancer	0.000254	0.000459	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CTNNB1—cervical cancer	0.000253	0.000457	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—FGFR3—cervical cancer	0.000253	0.000456	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—STAT3—cervical cancer	0.00025	0.000451	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOTCH2—cervical cancer	0.000248	0.000447	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CA9—cervical cancer	0.000248	0.000447	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—cervical cancer	0.000243	0.000438	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MTHFR—cervical cancer	0.000238	0.000431	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TERT—cervical cancer	0.000238	0.000429	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—FGFR3—cervical cancer	0.000236	0.000427	CbGpPWpGaD
Trametinib—MAP2K2—Disease—FGFR3—cervical cancer	0.000233	0.000421	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH2—cervical cancer	0.000232	0.000419	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—cervical cancer	0.000227	0.00041	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOTCH1—cervical cancer	0.000219	0.000395	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FGFR3—cervical cancer	0.000218	0.000394	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CASP8—cervical cancer	0.000216	0.00039	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—cervical cancer	0.000214	0.000387	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOTCH1—cervical cancer	0.000205	0.00037	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HES1—cervical cancer	0.000203	0.000367	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CASP8—cervical cancer	0.000202	0.000365	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—cervical cancer	0.000201	0.000362	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HES1—cervical cancer	0.00019	0.000343	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TERT—cervical cancer	0.000178	0.000321	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MTOR—cervical cancer	0.000178	0.000321	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CD4—cervical cancer	0.000177	0.00032	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TERT—cervical cancer	0.000167	0.000301	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MTOR—cervical cancer	0.000166	0.0003	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD4—cervical cancer	0.000166	0.0003	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MTOR—cervical cancer	0.000164	0.000296	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD4—cervical cancer	0.000164	0.000296	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGFR3—cervical cancer	0.000163	0.000295	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CTNNB1—cervical cancer	0.000158	0.000285	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MTOR—cervical cancer	0.000154	0.000277	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOTCH1—cervical cancer	0.000153	0.000277	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD4—cervical cancer	0.000153	0.000277	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGFR3—cervical cancer	0.000153	0.000276	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTNNB1—cervical cancer	0.000147	0.000266	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CTNNB1—cervical cancer	0.000145	0.000263	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH1—cervical cancer	0.000143	0.000259	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—cervical cancer	0.000137	0.000248	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—cervical cancer	0.000137	0.000247	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CTNNB1—cervical cancer	0.000136	0.000246	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CA9—cervical cancer	0.000133	0.00024	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—cervical cancer	0.000129	0.000232	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—cervical cancer	0.000128	0.000231	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—cervical cancer	0.000127	0.000229	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—cervical cancer	0.000125	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—cervical cancer	0.000119	0.000214	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—cervical cancer	0.000117	0.000211	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—cervical cancer	0.000115	0.000208	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MTOR—cervical cancer	0.000115	0.000207	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—cervical cancer	0.000108	0.000195	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MTOR—cervical cancer	0.000108	0.000194	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—cervical cancer	0.000106	0.000191	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNB1—cervical cancer	0.000102	0.000184	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MTHFR—cervical cancer	0.000101	0.000181	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—cervical cancer	9.89e-05	0.000179	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNB1—cervical cancer	9.53e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—cervical cancer	8.88e-05	0.00016	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—cervical cancer	8.31e-05	0.00015	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—cervical cancer	8.07e-05	0.000146	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—cervical cancer	7.55e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—cervical cancer	6.78e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—cervical cancer	6.34e-05	0.000114	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTHFR—cervical cancer	5.39e-05	9.74e-05	CbGpPWpGaD
